qPCR

ICON’s bioanalytical laboratories offer qPCR bioanalytical techniques to support the development of new drug modalities.

qPCR can support a wealth of different assay types needed for development of traditional drugs (small and large molecules), as well as for new modalities such as oligonucleotides and other cell and gene therapies. ICON has developed strong expertise in a range of qPCR assay types. Each assay presents its own challenges, expectations and acceptance criteria. This wealth of experience provides ICON with a strong foundation to utilise qPCR assays to support all types of drug development programs.

Our state-of-the-art bioanalytical laboratories have experienced teams of lab analysts, scientists and project managers working on qPCR assays to support various clinical trial outcomes. Examples include:

mRNA as PD marker in whole blood, PAXgene® and plasma
mRNA from a range of animal tissue types
mRNA expression in corneal epithelium from human impression cytology samples
microRNA from plasma samples as a biomarker
Quantitative testing of a human virus in plasma and urine, including different subtypes
Routine mycoplasma testing to support in-house cell culture activities
SNP genotyping
Simultaneous microRNA and mRNA isolation from the same sample

Equipment

ICON has invested in a wide variety of qPCR instrumentation and equipment. Using these systems we have built a laboratory capable of developing and implementing many different assay types for DNA, mRNA, miRNA and other oligonucleotides from both liquid matrices and tissues. Sample throughput can be scaled up, enabling fast turnaround of results for larger (pre-)clinical studies.

We have built a framework of procedures to enable flexibility in the procedures where needed, allowing us to run both exploratory assays and regulated bioanalytical work in the most efficient manner. We have also made significant efforts to automate as many of the assay steps as possible to generate the most reproducible (precise) results and to further improve throughput. This includes robotic systems for nucleic acid isolation and using Hamilton Microlab STAR robot systems for combining assay components into reaction wells.

Bringing benefits to your study:

Robust method development and tailored solutions: ICON can develop and validate reliable qPCR methods that align with the expectations and acceptance criteria specific to each assay, minimizing the risk of errors. The diverse experiences allow the team to quickly identify and address challenges, leading to faster resolution and less downtime in the development process.

Expert guidance: A team of subject matter experts ensures that best practices are followed, helping to navigate complex regulatory environments and maintain compliance.

Quality assurance: ICON's familiarity with industry standards enhances the reliability and reproducibility of results, which is critical for successful drug development and approval.

Data integrity: With rigorous quality control measures in place, ICON ensures that the data generated from qPCR assays is accurate and trustworthy, supporting informed decision-making.

ICON’s bioanalytical laboratories offer qPCR bioanalytical techniques to support the development of new drug modalities.

Equipment

Bringing benefits to your study:

In this section

Connect with us